Latest Licensing Agreements News

BTC Health has transformed its decade-long license agreement with Arna Pharma into an indefinite partnership, gaining royalties from Singapore and Malaysia sales and first rights to new pharmaceutical products in Australia and New Zealand.

Neuren Pharmaceuticals has received a significant cash inflow of approximately US$50 million following the sale of a Priority Review Voucher linked to its Rett syndrome treatment. This milestone underscores the growing value of Neuren’s neurological drug portfolio and its partnership with Acadia Pharmaceuticals.

PARKD has inked a pivotal five-year exclusive licensing agreement with Fielders, a BlueScope Steel division, to commercialise its innovative MDSB® and MDSS® products in Australia and explore international expansion.

AdAlta has fast-tracked its cellular immunotherapy growth by signing two new term sheets for clinical-stage CAR-T products from Asia, pivoting to focus on in-licensing and clinical trials while winding down internal R&D on its antifibrotic drug AD-214.

PARKD Ltd has secured a 7-day extension to its exclusive licence agreement with Fielders Steel Roofing, following successful proof-of-concept projects for its Metal Deck Support System. The extension aims to finalise terms for a longer-term commercial partnership.

Cosmos Exploration has taken a major step into the global lithium market by signing an exclusive option agreement to acquire EAU Lithium Pty Ltd, unlocking access to Bolivia’s vast lithium resources and pioneering advanced extraction technology.

Wellnex Life Limited reported a 36% rise in Q2 FY25 cash receipts and record monthly sales, while advancing its dual listing on the London Stock Exchange and expanding into the UK market.

Emyria Limited reports strong progress in its MDMA and psilocybin-assisted therapy programs alongside a successful $2.525 million capital raise, positioning the company for expanded mental health treatment services.

NOVONIX has advanced its position in the battery materials sector with a conditional US$754 million loan commitment from the U.S. Department of Energy and binding offtake agreements with automotive giants Stellantis and PowerCo. These milestones underpin its expansion plans for synthetic graphite production in North America.

Vectus Biosystems reports completion of Phase Ib trials for its lead drug VB0004 and a robust cash position bolstered by a significant R&D tax refund, setting the stage for licensing discussions.

BCAL Diagnostics is poised to launch its innovative BREASTEST® breast cancer diagnostic test in early 2025, backed by recent NATA accreditation, patent acceptance, and a $2.6 million R&D tax offset.

archTIS Limited reported a 12% increase in annual recurring revenue to $4 million and achieved net positive cash flow from operations, while signing a binding term sheet to acquire Direktiv’s assets, signaling strategic growth in data-centric security.